【摘要】 目的研究不同剂量瑞舒伐他汀治疗急性冠脉综合征(ACS)患者的临床效果及对其血清炎症因子的影响。方法选择2013年9月—2014年10月治疗急性冠脉综合征的患者142例,随机将其分成大剂量组和常规剂量组,每组各71例。大剂量组每天给予患者服用20mg瑞舒伐他汀,常规剂量组每天给予患者服用10mg瑞舒伐他汀。观察两组患者治疗效果及血清炎症因子的浓度变化。结果两组患者在血清炎症因子及不良心脏事件发生率方面相比,差异均有统计学意义(P<0.05);两组患者在用药安全性方面相比,差异无统计学意义(P>0.05)。结论采用大剂量瑞舒伐他汀治疗急性冠脉综合征效果显著,能有效的预防不良心脏事件发生,降低血清炎症因子,不额外增加不良反应,可推广应用。更多还原

【Abstract】 Objective To research the effects of different doses of atorvastatin in the treatment of patients with acute ACS and its effect on serum inflammatory factors. Methods Totally 142 patients with acute coronary syndromes,who were to our hospital for treatment in September 2013 to October 2014,were randomly divided into routine dose group and high dose group with 71 cases in each group. Patients of high dose group were given 20 mg rosuvastatin; Patients of daily routine dose group were given 10 mg rosuvastatin. The therapeutic effect and the concentration changes of serum inflammatory factors of the two groups were observed. Results Two groups of patients were compared on serum inflammatory factors and adverse cardiac events occurring rate,and the differences were statistically significant( P < 0. 05); There was no significant difference between the two groups in the safety of medication( P > 0. 05). Conclusion The treatment effect of high-dose rosuvastatin on patients with acute coronary syndrome( ACS) is remarkable. It can effectively prevent adverse cardiac events and reduce serum inflammatory factors,and it had no additional adverse reactions. It can be popularized and applied.更多还原